Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.625
High: 0.625
Low: 0.625
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

Mon, 29th Oct 2018 10:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC, up 4.7%. The Asia-focused bank reported an "encouraging" third quarter with consensus beating profit. For the three months ended September, pretax profit rose 28% to USD5.92 billion from USD4.62 billion the year prior. Excluding the impact of currency translation, pretax profit rose 16% on the year before. Revenue rose 1.6% to USD13.80 billion from USD13.58 billion the year before. Revenue performance was driven by "strong" growth in all of HSBC's three main global businesses. Shore Capital called HSBC's third-quarter results strong, saying adjusted pretax profit of USD6.19 billion, up 16% on year, was 8% better than consensus at USD5.73 billion and 6% better than Shore's own forecast of USD5.86 billion. Group operating expenses decreased 6.8% to USD7.97 billion from USD8.55 billion the year before. This is largely due the bank's significant items decreasing to USD228 million from USD762 million. The large drop in one-off costs included the non-recurrence of "costs to achieve", which had been USD700 million in the year-ago comparative period. ----------Shire, up 2.5%. Japanese drugmaker Takeda Pharmaceutical said it is considering selling an experimental inflammatory bowel disease drug that is under development by its takeover target Shire. Takeda confirmed its discussion with the European Commission regarding potential overlap between its marketed product Entyvio and Shire's pipeline compound SHP647. SHP647 is a human monoclonal antibody that targets mucosal addressin cell adhesion molecule, which is currently undertaking phase III clinical trials. Takeda has proposed a potential divestment of SHP647 and associated rights. Takeda confirmed on Monday that there are no discussions with the European Commission regarding any other marketed products or assets in the pipeline.----------FTSE 100 - LOSERS----------Just Eat, down 5.2%. Peel Hunt downgraded the online takeaway platform to Sell from Buy. The broker said the rise of rivals Uber and Deliveroo could lead to the demise of Just Eat, given the two can outspend the FTSE 100 constituent and outperform in the smartphone space. Bloomberg in September reported that ride-hailing app Uber - which also offers a food delivery service Uber Eats - was in early discussions with Deliveroo, as part of its strategy to invest and partner with rivals ahead of its planned initial public offering next year.----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 20%. The cancer-focused pharmaceutical company's shares rose after a key research study demonstrated positive results for its Nuvec delivery system. Since June, N4 Pharma has conducted a research study to determine the level of immune response Nuvec can deliver, using both messenger RNA and plasmid DNA when combined with the antigen Ovalbumin. The results demonstrates that the Nuvec themselves have a clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA antigens compared to other delivery systems. As Nuvec will not require an additional adjuvant when formulating a vaccine when used as a delivery system, this could lead to reduced production costs for a final vaccine, as less antigen would be required. In addition, the level of immune response generated by Nuvec particles is within acceptable levels, showing no adverse toxicity.----------Lok'n Store, up 10%. The storage company said its earnings grew in its recently ended financial year following a rise in occupancy and store numbers. Lok'n Store said pretax profit in the year to the end of July improved to GBP5.3 million from GBP4.0 million reported a year earlier, as revenue rose to GBP17.8 million from GBP16.7 million. The company noted the result was driven by occupancy increases in both old and new stores. Tight control over operating costs led to a 2% increase in self-storage margins, which has also contributed in pushing the company's profit to "record level". Lok'nStore declared an annual dividend of 11 pence per share, up 10% from 10p paid the year prior.----------OTHER MAIN MARKET AND AIM - LOSERS----------Warpaint Group, down 43%. The colour cosmetics supplier said the UK market has remained challenging for the company with softening sales, even as it expects a rise in profit and revenue for 2018. Warpaint said its UK market, which accounted for 44% of group's sales in the first half of the year, saw further softening following the end of the interim period due to retailers reducing their stock levels and Christmas orders. The group said the reduction in previously anticipated UK sales will hurt its performance for 2018, which will not be completely offset by an outperformance in its sales territories overseas. As at September 30, sales in the US were up 60% compared to the same period in 2017, and sales in the EU were up 14% year-on-year.----------Gama Aviation, down 17%. The aviation service provider lowered its full-year expectations after trading in some of its divisions has not improved "sufficiently" during the second half of 2018. Gama said it now expects the annual underlying operating profit to be USD3 million below its original expectations. In 2017, Gama generated underlying operating profit of USD18.7 million. On a divisional basis, the company's Air unit saw stable performance in Europe, Middle East & Asia. However, profit from the US is now below Gama's expectations due to slower-than-anticipated growth in charter and aircraft management revenue. In Asia, Gama's associate China Air Services has continued to underperform with the unexpected loss of contracts significantly harming margins. ----------
More News
8 Feb 2019 13:18

N4 Pharma Raises GBP1.1 Million In Share Placing To Fund Nuvec System (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC on Firday said it raised GBP1.1 million in a placing of 10.5 million shares at 10 pence each.N4 Pharma shares were trading down 18% at 10.10p each on

Read more
8 Feb 2019 12:00

N4 Pharma raises £1.05m in placing to advance vaccine delivery system

(Sharecast News) - Specialist pharmaceutical company N4 Pharma said on Friday that it has raised £1.05m before expenses in a placing of 10.5m new ordinary shares to fund its vaccine delivery system.

Read more
20 Dec 2018 15:06

N4 Pharma extends 'Nuvec' licence agreement with Aussie university firm

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has extended the terms of its licence agreement with UniQuest - a University of Queensland company - for the exploitation of its novel delivery system 'Nuvec' on Thursday.

Read more
28 Nov 2018 11:30

N4 Pharma bears more good news on its Nuvec particles

(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated on the latest key research findings for its 'Nuvec' delivery system on Wednesday.

Read more
28 Nov 2018 11:20

N4 Pharma Shares Boosted By Positive Nuvec System Results

LONDON (Alliance News) - N4 Pharma PLC shares were up on Wednesday after encouraging research on its Nuvec delivery system.Shares in the pharma company were up 26% at 10.74 pence on Nuvec a

Read more
5 Nov 2018 10:57

WINNERS & LOSERS SUMMARY: Micro Focus Rises On Outlook And Buyback

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Micro Focus up

Read more
29 Oct 2018 11:32

N4 Pharma pleased with latest test results on 'Nuvec'

(Sharecast News) - Specialist pharmaceutical company N4 Pharma updated the market on the latest key research findings for its 'Nuvec' delivery system on Monday, reporting that the Nuvec particles had a "clear adjuvant effect" to help deliver a level of immune response for both the mRNA and pDNA OVA antigens, comparable to that of existing delivery systems.

Read more
29 Oct 2018 09:46

N4 Pharma Shares Rise Following Positive Research Results For Nuvec

LONDON (Alliance News) - Shares rose in N4 Pharma PLC on Monday as a key research study demonstrated positive results for the company's Nuvec delivery system.Shares in the vaccine and a

Read more
2 Oct 2018 12:08

N4 Pharma Commissions Research Programme With Gowans Laboratory

LONDON (Alliance News) - N4 Pharma PLC said Tuesday it commissioned a research program with the Gowans laboratory in the University of Adelaide to investigate its Nuvec system's potential to a

Read more
24 Sep 2018 10:48

WINNERS & LOSERS SUMMARY: Thomas Cook Slumps After Profit Warning

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Sky,

Read more
20 Sep 2018 10:30

N4 Pharma To Close Generic Unit After Failed Trials; Loss Narrows

LONDON (Alliance News) - Shares in N4 Pharma PLC dropped on Thursday as the company said it will close its Generic unit after the failure of Sildenafil trials.Shares in the pharmaceutical a

Read more
20 Sep 2018 10:30

WINNERS & LOSERS SUMMARY: Rio Tinto Up On Plan To Return Sale Proceeds

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rio up 1.9%.

Read more
20 Sep 2018 09:49

N4 Pharma calls it a day on generics division, losses widen

(Sharecast News) - After undertaking a strategic review, N4 Pharma directors have decided to discontinue further development of Sildenafil and shutter the rest of its generics division.

Read more
9 Jul 2018 10:08

WINNERS & LOSERS SUMMARY: Centamin Falls After Gold Production Drops

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Just up 2.4%.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.